Know Cancer

forgot password

Randomized Phase IIb Study of Sorafenib Dose Escalation in Patients With Previously Untreated Metastatic Renal Cell Carcinoma (RCC)

Phase 2
18 Years
Not Enrolling
Renal Cell Carcinoma

Thank you

Trial Information

Randomized Phase IIb Study of Sorafenib Dose Escalation in Patients With Previously Untreated Metastatic Renal Cell Carcinoma (RCC)

Inclusion Criteria:

- Age ≥18 years old.

- Diagnosis of unresectable/metastatic renal cell carcinoma (RCC). Nonclear cell
histology is permitted (except for medullary, collecting duct, or sarcomatoid >50% of
specimen). Prior metastasectomy is permitted as long as there is measurable disease
at time of consent.

- Karnofsky Performance Status of 50% or greater at study entry.

- Adequate bone marrow, liver and renal function as assessed by the following: o
Hemoglobin ≥ 9.0 g/dL. o ANC ≥ 1500/mm3. o Platelet count ≥ 100,000/mm3. o Total
bilirubin ≤ 1.5 ULN. o ALT and AST ≤ 2.5 × ULN (≤ 5 × ULN for patients with liver
involvement). o Creatinine ≤ 1.5 × ULN.

- Women of childbearing potential must have a negative serum or urine pregnancy test
performed within 7 days prior to the start of treatment.

- Women of childbearing potential and sexually active men must agree to use adequate
barrier contraception prior to study entry, for the duration of study participation,
and for at least three months after the last administration of sorafenib.

- INR < 1.5 or a PT/ PTT within normal limits. Patients receiving anti-coagulation
treatment with an agent such as warfarin or heparin may be allowed to participate.
For patients on warfarin, the INR should be measured prior to initiation of sorafenib
and monitored at least weekly, or as defined by the local standard of care, until INR
is stable.

- Ability to understand and the willingness to sign a written informed consent. A
signed informed consent must be obtained prior to any study specific procedures.

Exclusion Criteria:

- Prior systemic anticancer treatment for metastatic disease, including investigational

- Prior treatment with bevacizumab, sunitinib, or sorafenib even in the adjuvant

- Prior cytokine therapy with interleukin (IL)-2 or interferon (IFN) for metastatic

- Active malignancy other than RCC (except non-melanoma skin cancer) within 5 years of

- Hemodialysis or peritoneal dialysis.

- Treatment with radiotherapy within 2 weeks of enrollment.

- Cardiac disease: Congestive heart failure Class II or higher per NYHA. Patients must
not have unstable angina (anginal symptoms at rest) or new onset angina (began within
the last 3 months) or myocardial infarction within the past 6 months.

- Uncontrolled CNS metastases. All patients must undergo a CT) scan/MRI of the brain
to exclude brain metastasis. Patients with adequately treated CNS disease may be
considered for participation as long as the first dose of sorafenib is 4 weeks after
completion of CNS therapy.

- Uncontrolled hypertension defined as SBP > 150 mmHg or DBP > 90 mmHg, despite optimal
medical management.

- Active clinically serious infection > Grade 2 per the CTCAE v3.

- Thrombolic or embolic events such as a cerebrovascular accident including transient
ischemic attacks within the past 6 months.

- Pulmonary hemorrhage/bleeding event ≥ Grade 2 per CTCAE v3.0 within 4 weeks of
administration of the first dose of study drug.

- Any other hemorrhage/bleeding event ≥ Grade 3 per CTCAE v3.0 within 4 weeks of
administration of the first dose of study drug.

- Serious non-healing wound, ulcer, or bone fracture.

- Evidence or history of bleeding diathesis or coagulopathy.

- Major surgery, open biopsy or significant traumatic injury within 4 weeks of
administration of the first study drug dose.

- Use of St. John's Wort, rifampin (rifampicin), phenytoin, Phenobarbital,
carbamazepine, dexamethasone.

- Known or suspected allergy to sorafenib or any agent given in the course of this

- Any condition that impairs patient's ability to swallow whole pills.

- Any malabsorption problem.

- Pregnancy or lactation.

Type of Study:


Study Design:

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

The primary endpoint will be the overall response rate (CR + PR) determined by the Response Evaluation Criteria in Solid Tumors (RECIST) criteria.

Outcome Time Frame:

Every 8 Weeks

Safety Issue:


Principal Investigator

Vasily Assikis, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:



United States: Institutional Review Board

Study ID:




Start Date:

January 2008

Completion Date:

April 2011

Related Keywords:

  • Renal Cell Carcinoma
  • Renal Cell Carcinoma
  • Kidney Cancer
  • Carcinoma
  • Carcinoma, Renal Cell



Wilshire Oncology Medical Group, Inc. Rancho Cucamonga, California  91730
Gaston Hematology and Oncology Gastonia, North Carolina  28054
Hematology Oncology Centers of the Northern Rockies Billings, Montana  59101
The West Clinic Memphis, Tennessee  38120
Northwest Georgia Oncology Centers Marietta, Georgia  30060
Mid-Illinois Hematology and Oncology Associates, Ltd. Normal, Illinois  61761
Northeast Georgia Cancer Care Athens, Georgia  30607
Advanced Medical Specialties Miami, Florida  33176
Central Georgia Cancer Care Macon, Georgia  31201
Clopton Clinic Jonesboro, Arkansas  72401
Peachtree Hematology Oncology Consultants Atlanta, Georgia  30309
Pacific Oncology, PC Portland, Oregon  97225
The Lancaster Cancer Center, Ltd Lancaster, Pennsylvania  17605